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We have shown in a murine model system for acute, lethal cytomegalovirus (CMV) disease in the
immunocompromised natural host that control of virus multiplication in tissues, protection from virus-caused
tissue destruction, and survival are mediated by virus-specific CD8+ CD4- T lymphocytes. Protection from a
lethal course of disease did not result in a rapid establishment of virus latency, but led to a long-lasting,
persistent state of infection. The CD8- CD4+ subset of T lymphocytes was not effective by itself in controlling
murine CMV (MCMV) multiplication in tissue or essential for the protective function of the CD8+ CD4-
effector cells. The antiviral efficacy of the purified CD8+ CD4- subset was not impaired by preincubation with
fibroblasts that presented viral structural antigens, but was significantly reduced after depletion of effector cells
specific for the nonstructural immediate-early antigens of MCMV, which are specified by the first among a
multitude of viral genes expressed during MCMV replication in permissive cells. Thus, MCMV disease
provides the first example of a role for nonstructural herpesvirus immediate-early antigens in protective
immunity.
Cytomegalovirus (CMV) disease is one of the leading
reasons for mortality in immunocompromised patients. Op-
portunistic primary or recurrent CMV infection is involved
in the acquired immunodeficiency syndrome (22, 23) and
also causes interstitial pneumonia in bone marrow transplant
recipients after iatrogenic immunosuppression (21, 25). In
the immunocompetent host, CMV infection is effectively
controlled, and virus persists in a latent state. CD8 (T8)-
positive cytolytic T lymphocytes (CTL) have been impli-
cated in the recovery from CMV infection (25). Viral gene
expression in lymphocytes and monocytes of seropositive
patients was found to be arrested after the expression of
immediate-early (IE) genes (33), the first set of herpesvirus
genes transcribed under permissive conditions (8), and CTL
have been reported to recognize infected cells at an early
time during the viral replication cycle (1).
We have studied protective immunity to CMV in a murine
model system with particular respect to the virus-specified
antigens involved. The present state of knowledge can be
briefly reviewed as follows.
(i) During acute, intraplantar infection of immunocompe-
tent BALB/c mice, replication of murine CMV (MCMV) is
restricted to glandular epithelial cells in the salivary glands,
while after immunodepletion by total-body gamma irradia-
tion, virus can colonize several other tissues, including lung
tissue, in which it causes interstitial pneumonia (32). (ii)
Protective immunity can be conferred to immunodepleted
recipients by transfer of specifically sensitized T lympho-
cytes that contain the CD8 (Lyt-2)-positive subset (32). The
antiviral efficacy of such cells can be enhanced by applica-
tion of interleukin 2 (IL-2) in vivo (31). (iii) A high proportion
of the sensitized CTL precursors contained in donor T
lymphocyte populations are specific for cell membrane anti-
gen(s) specified by IE genes. IE antigens are nonstructural
viral antigens (29, 30). (iv) A particular IE membrane antigen
defined by the Ld-restricted CTL clone TEl (26) is expressed
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in L(H-2k) fibroblasts cotransfected with the major histo-
compatibility complex (MHC) gene Ld and IE genes of
MCMV (16, 17). In infected cells, this antigen can be
detected after enhanced, selective expression of IE genes
and also during the late phase of MCMV replication (27). (v)
The major IE protein of MCMV, pp89, has a regulatory
function in viral gene expression and is located in the
nucleus of the infected cell (10, 11, 13, 15, 16). Gene iel,
encoding pp89, lacks nucleotide sequences that would pre-
dict membrane-spanning domains (12).
Based on the finding that T lymphocytes of the CD8 subset
mediate protective immunity (31, 32), it has been a tacit
assumption in our working hypothesis that IE-specific CTL
perform a protective function. In this communication we
provide the first evidence that CD8-positive T lymphocytes
specific for IE antigens can protect from a lethal course of
infection.
MATERIALS AND METHODS
Short-term T-lymphocyte lines. In vivo-sensitized T lym-
phocytes were propagated in vitro as IL-2-dependent short-
term lines to deplete for other cell types before probing the
antiviral efficacy in immunodepleted cell transfer recipients.
The lymphocytes were derived from draining popliteal
lymph nodes of immunocompetent BALB/c (H-2d haplo-
type) donors 8 days after intraplantar infection with 105 PFU
of MCMV (strain Smith, VR-194; American Type Culture
Collection, Rockville, Md.) and expanded in vitro for 8 days
in round-bottomed 0.2-ml microcultures at a cell density of 5
x 104 cells per well in the absence of viral antigen and with
no feeder cells (28). The culture medium (minimal essential
medium alpha without nucleosides; GIBCO Laboratories;
for supplements see reference 26) contained 100 U (0.88
pmol) of recombinant human IL-2 (rhIL-2) (lot 89050/84802)
with a specific activity of 7.3 x 106 U/mg of protein (gener-
ously supplied by the Sandoz Forschungsinstitut, Vienna,
Austria). Lymphokine-activated killer (LAK) cells (34) were
generated by propagating popliteal lymph node-derived lym-
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of early- and late-phase genes. Selective presentation of viral
structural antigens (S-MEF, S-KD2SV) was achieved by
infection with high doses of MCMV (200 PFU/cell) in the
presence of actinomycin D to prevent de novo antigen
synthesis (26, 29).
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RESULTS
Antiviral efficacy of purified T-lymphocyte subsets. Previ-
ous studies (31, 32) have demonstrated that depletion of
CD8-positive lymphocytes abrogates the ability of a sensi-
tized lymph node cell population to control MCMV multi-
plication in tissues of immunodepleted cell transfer recipi-
ents. Cooperation with CD4-positive lymphocytes proved to
be dispensable, while a requirement for donor-derived CD4-
negative accessory cells has not been formally excluded. For
relating antigen specificity to antiviral in vivo function of
effector cells, we have now studied the properties of purified
T-lymphocyte subsets after in vitro IL-2-mediated clonal
expansion in the absence of antigen.
The composition of in vitro IL-2-propagated lymphocyte
populations, derived from draining lymph nodes of infected
donors, was determined by cytofluorometric analysis (Fig.
1). The population comprised two distinct subsets: CD8+
CD4- lymphocytes (left column in the array of fluorescence
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histograms) and CD8- CD4+ lymphocytes (right column).
There was no indication of the existence of a non-CD4
non-CD8 population, demonstrating the depletion of B lym-
phocytes and accessory cell types during clonal expansion of
T lymphocytes. Treatment with anti-CD8 MAb plus comple-
ment (second row in the array of fluorescence histograms)
yielded a pure CD8- CD4+ population, while treatment with
anti-CD4 MAb plus complement (third row) yielded a pure
CD8+ CD4- population. The CD8 population contained cells
with a low CD8 antigen density, a phenomenon that can be
observed also with cloned long-term CTL lines (26).
The in vivo antiviral activity of these purified, accessory
cell-depleted T-lymphocyte subsets was probed by prophy-
lactic adoptive transfer into immunodepleted, lethally in-
fected recipient mice (32), employing the lungs as a sensitive
indicator site of MCMV replication (Fig. 2). LAK cells (34)
generated by IL-2-mediated in vitro activation of lympho-
cytes derived from popliteal lymph nodes of noninfected
donors did not affect virus multiplication in the lungs of
transfer recipients (compare the virus titers in columns A
and B; A versus Bi, P > 0.1; A versus B2, P > 0.1). This
control demonstrated that under the conditions of the exper-
iment and within the dose range tested, an antiviral function
could not be ascribed to LAK cells. Compared with it,
nonseparated specifically sensitized lymphocyte populations
(composed as depicted in Fig. 1, first row) markedly limited
MCMV multiplication in lung tissue (compare columns A
and C in Fig. 2). Note that transfer of 20,000 specific T
lymphocytes proved to be significantly more effective than
transfer of 10-fold this amount ofLAK cells (B2 and Cl, P =
0.01). A pure CD8- CD4+ population was not able to exert
no transfer LAK
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FIG. 2. Identification of the in vivo antiviral T-lymphocyte sub-
set. The in vivo antiviral efficacy of lymphocytes was tested in
lethally infected recipients by means of adoptive transfer. Virus
titers in the lungs were determined at day 14 postinfection in five
randomly collected surviving recipients per group. Individual titers
are signified by closed circles, and median values are marked by
horizontal bars. (A) No transfer of lymphocytes. (B) Transfer of 2 x
104 (lane 1) and 2 x 105 (lane 2) lymphokine (IL-2)-activated
nonspecific killer cells. (C) Transfer of 2 x 104 (lane 1) and 2 x 105
(lane 2) specifically sensitized, IL-2-propagated T lymphocytes. (D)
Transfer of 2 x 105 group C lymphocytes depleted of the CD8-
positive subset. (E) Transfer of 2 x 105 group C lymphocytes
depleted of the CD4-positive subset.
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FIG. 3. In situ demonstration of the antiviral effect of CD8-
positive T lymphocytes. Infected cells in thin sections (5 to 10 ,um)
of lung tissue were visualized at day 14 postinfection by in situ
hybridization of viral nucleic acid with a mixture of plasmid-cloned
MCMV DNA fragments as specific probe. (a) Transfer of 2 x 105
CD4-positive T lymphocytes; for virus titer see Fig. 2, column D. (b)
Transfer of 2 x 105 CD8-positive T lymphocytes; for virus titer see
Fig. 2, column E. Arrows in panel a point to clusters of infected
cells. Both sections are shown at the same magnification. Bar, 30
,um.
an antiviral effect (D versus A, P > 0.1), while a pure CD8+
CD4- population was as effective as the unseparated popu-
lation (C2 and E, P > 0.1).
Evidence for prevention of virus-mediated histopathology
by transfer of CD8+ CD4- T lymphocytes was documented
by in situ hybridization of lung tissue sections with cloned
genomic fragments ofMCMV (Fig. 3). While after transfer of
T lymphocytes depleted of the CD8 subset several clusters
of infected cells could be detected with ease in each lung
tissue section at day 14 postinfection (Fig. 3a), MCMV DNA
was only rarely detectable in lung tissue by screening a
series of sections (Fig. 3b) after transfer of CD8+ CD4- T
lymphocytes. The more dispersed appearance of the tissue
in Fig. 3a reflects the widening of the alveolar septa during
interstitial MCMV pneumonia, as has been demonstrated in
a previous report (32), whereas the tissue in Fig. 3b was
phenotypically normal. This finding verified that the antiviral
activity of CD8 effector cells was not accompanied by
cell-mediated histopathology, but rather protected from vi-
rus-mediated tissue destruction.
In conclusion, the antiviral effector function in vivo can be
assigned to the CD8-positive subset of specifically sensitized
T lymphocytes. The CD4-positive subset was neither effec-
tive by itself nor essential for the function of the CD8
effector cells.
CD8-positive T lymphocytes specific for IE antigens control
MCMV replication in vivo. In Fig. 4, the in vitro cytolytic
activity of a purified CD8-positive effector cell population is
related to its in vivo antiviral function. In that experiment,
the frequency of IL-2-receptive, i.e., sensitized, CTL pre-
cursors (IL-CTLp [28, 30]) specific for antigens displayed by
fibroblasts that selectively expressed IE genes of MCMV
was estimated by limiting-dilution analysis (maximum-
likelihood method [5]) to be 1 of 7,680 (95% confidence
range, 1 of 5,550 to 1 of 10,640; P = 0.78), which was in good
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FIG. 4. In vitro effect and in vivo function of CD8-positive T
lymphocytes specific for IE antigen(s) of MCMV. A purified CD8+
CD4- effector cell population (Fig. 1, third row) was incubated for
antigen-specific depletion on monolayers of noninfected fibroblasts
(A; MEF) or of fibroblasts that either presented viral structural (S)
antigens (B; S-MEF) or expressed viral IE antigens (C; IE-MEF).
CTL activity and specificity in vitro (scale on the left, open symbols)
were determined by lysis of the target cells S-KD2SV (open squares)
and IE-KD2SV (open circles) at the effector-to-target cell ratios
indicated. The dashed line represents the significance level for
specific lysis, defined by the upper 95% confidence limit of sponta-
neous lysis. The in vivo antiviral function was tested by adoptive
transfer of 20,000 cells (equal to the number of effector cells at the
in vitro effector-to-target cell ratio of 20). The virus titers in the
lungs of five transfer recipients per group were determined individ-
ually at day 14 postinfection (scale on the right, closed circles). The
median values are marked by horizontal bars.
accordance with previous estimates (30), while the fre-
quency of IL-CTLp specific for viral structural (S) antigens
was <1 of 80,000.
The polyclonal lymphocyte population obtained after IL-
2-mediated expansion was first depleted of the CD4 subset
(Fig. 1, third row) and then incubated for antigen-specific
depletion on fibroblast monolayers. CD8-positive lympho-
cytes recovered from noninfected monolayers (Fig. 4A)
lysed syngeneic IE target cells (IE-KD2SV, H-2d) with high
efficacy. The recognition of IE antigens was MHC restricted,
as MHC-mismatched IE target cells (IE-B6/WT-3, H-2b)
were not lysed (not depicted). Also not lysed were syngeneic
fibroblasts that displayed viral S antigens (S-KD2SV). Note
that S-KD2SV was an appropriate target for lysis by CTL
clones specific for S determinants ofMCMV (26). This result
thus documented the absence of S-specific CTL in that
effector cell population and reconfirmed that IE antigens and
S antigens are separate entities recognized by different CTL
(26, 29). Accordingly, preincubation on monolayers carrying
S antigens did not affect the anti-IE-directed lytic efficacy of
the population (Fig. 4B), whereas contact with monolayers
that expressed IE genes profoundly did so (Fig. 4C).
The in vivo antiviral efficacies of the three selected popu-
lations were compared by testing the ability of 20,000 cells to
limit MCMV multiplication in the lungs of immunodepleted
recipients (Fig. 4). While preincubation on S monolayers had
no significant effect (A and B, P = 0.1), depletion of
IE-specific effector cells on IE antigen-expressing monolay-
ers (panel C) resulted in a significant increase in virus titers
(A and C, P = 0.005; B and C,P = 0.005; and A and B versus
C, P < 0.001) to almost the control level (Fig. 2, column A).
Altogether, these data established that CD8-positive lym-
phocytes specific for IE antigens of MCMV are able to limit
virus multiplication in vivo.
Protection from a lethal course of disease and establishment
of persistent infection. Two important questions remained to
be answered: (i) was the numerically and histologically
significant antiviral effect also significant quo ad vitam, and
(ii), if so, did infection in surviving cell transfer recipients
then attain a latent or a persistent state (9)?
For the correct evaluation of the results shown in Fig. 5, it
is important to recollect some basic facts of the experimental
model detailed in a previous report (32). Immunodepletion as
a consequence of total-body gamma irradiation with a radi-
ation dose of 6 Gy (equal to a lethal dose referred to as
LD50/30 in reference 37) causes, on average, 50% of adult (8-
to 10-week-old) female BALB/c mice to die within an
observation period of 30 days. Without exception, im-
munodepleted mice die of acute CMV disease after infec-
tion, while immunocompetent mice all survive.
CD8-positive lymphocytes selected for the recognition of
viral nonstructural antigens (Fig. 4B) were transfused into
lethally infected recipients (Fig. 5). Without lymphocyte
transfer, all mice died within a demarcated period of time
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FIG. 5. Protection from a lethal course of MCMV disease by
CD8-positive T lymphocytes. The diagram illustrates the mortality
in a set of 20 immunodepleted, infected mice (shaded area) and the
protection mediated by prophylactic adoptive transfer of 2 x 104
(group I, closed circles), 2 x 105 (group II, open squares), and 1 x
106 (group III, closed squares) CD8+ CD4- T lymphocytes, which
were selected for the recognition of viral nonstructural antigens (as
shown in Fig. 4B). In one of the recipients (in group II) that had
survived until the end of the 30-day monitoring period, necrosis at
the plantar site of infection was not cured. This individual died at
day 42 postinfection (not depicted).
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postinfection (Fig. 5, shaded area). The terminal stage of
CMV disease was signified by a severe wasting syndrome,
extensive hemorrhages spreading from the plantar site of
infection, and necrosis in several tissues, including the
lungs, the liver, and the adrenal glands. Transfer of only
20,000 specific lymphocytes significantly retarded death
from CMV disease, and 3 of 20 mice survived (Fig. 5, graph
I). Note that hemorrhages in the footpad developed in all
mice until day 10 postinfection and were completely healed
in the survivors by day 30. Mortality could be further
reduced by increasing the number of lymphocytes trans-
ferred, but reached a plateau level (compare graphs II and
III). This result is well comprehensible, because antiviral T
lymphocytes cannot be expected to remedy radiation sick-
ness, but at best can annul the consequences of opportunis-
tic viral infection.
A month later, at day 60 postinfection, titers of MCMV in
tissue were determined for the salivary glands, the spleen,
and the lungs of survivors from all three lymphocyte transfer
groups (Fig. 6). With two exceptions (group I, recipient 3,
and group II, recipient 6), the presence of infectious virus in
the salivary glands indicated that viral latency was not
established. With one exception (group III, recipient 4), viral
replication had ceased in the spleen, while infectious virus
was detected in the lungs in two of three (group I), three of
six (group II), and two of seven (group III) recipients. The
individual scoring revealed only a few mismatches in the
rank of virus titers observed in salivary glands and lungs
(group II, recipients 2, 3, and 4). In these recipients, MCMV
was present in the salivary glands but not in the lungs.
Consistent with the known fact that salivary glands repre-
sent the most permissive site for MCMV replication (20, 32),
the reverse case was not observed, and the virus titers in the
salivary glands were significantly higher than those in the
lungs of the same individuals.
Seroconversion was observed in all individuals, indicating
autoreconstitution of humoral immunity, but there was no
correlation between MCMV-specific serum antibody titers
and virus titers in any of the organs tested (data not shown).
In conclusion, CD8-positive T lymphocytes specific for IE
antigens ofMCMV protected from a lethal course of disease
but did not prevent persistent infection.
DISCUSSION
Recent findings in viral immunology have established that
virion envelope glycoproteins are not the only viral gene
products that can be recognized by CTL in conjunction with
class I major histocompatibility glycoproteins. Antigenic
determinants can also be derived by antigen processing, i.e.,
by degradation or biochemical derivation, from nonglycosyl-
ated virion internal proteins (38-41) or from regulatory viral
proteins which are not constituents of the virus particle but
are present in transformed cells (2, 6).
Whether or not a significant role in eliciting protective
immunity can be ascribed to processing-dependent antigens
is a topic of current interest with possible relevance to future
design of vaccines. MCMV infection offers the advantage of
studying lethal virus disease, protection against it, and the
conditions for establishing persistent and latent infection in
the natural host.
There is a current debate about the T-lymphocyte CD
subset operative in vivo in the control ofMCMV disease. In
the BALB/c mutant nulnu, CD4 lymphocytes have been
reported to be the antiviral effector cells in the adrenal
glands (35). We have chosen the irradiated BALB/c mouse
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FIG. 6. Establishment of persistent MCMV infection. The sur-
vivors of the protection experiment shown in Fig. 5 (groups I, II,
and III) were screened at day 60 postinfection for the presence of
infectious MCMV in the salivary glands, the spleen, and the lungs.
The individuals in each group are signified by numbers according to
the rank of the virus titer in the salivary glands. The dashed line
represents the detection limit.
for a model because interstitial pneumonia caused by oppor-
tunistic primary or recurrent human CMV infection is a
clinical problem in leukemia patients after irradiation (21,
25). Our present data concur with our previous studies (31,
32) in the conclusion that control of virus multiplication in
the lungs is a function of the CD8 subset of specifically
sensitized T lymphocytes and prove in addition that purified
CD8+ CD4- effector cells do not require the help provided
by CD4 lymphocytes to protect against tissue destruction
and mediate survival.
The mechanism by which CD8 lymphocytes exert their
antiviral effect in vivo is still open to question, and a solution
of this problem is beyond the scope of this contribution. Two
aspects, however, deserve consideration. First, remarkably
few cells were required for conferring protection (Fig. 3 and
5), and second, only specifically sensitized lymphocytes
inhibited virus multiplication (Fig. 2). A seemingly low
probability for antiviral effector cells to encounter their
targets in vivo has been adduced as an argument in favor of
a lymphokine effect (18). Studies by Lukacher et al. (19) and
by Zinkernagel et al. (42) have provided evidence for direct
in vivo cytolysis by CTL. From recent work by Oldstone et
al. (24), it can be concluded that these mechanisms do not
necessarily exclude each other. In MCMV disease, control
of virus multiplication in the lungs by CD8 effector cells was
not accompanied by cell-mediated tissue destruction. This
finding, however, cannot be taken as evidence against direct
cytolysis. MCMV infection in tissue is focal, spreading from
single cells initially colonized by virus. The occurrence of
infected cells in distinct clusters (Fig. 3a) illustrates this fact.
Elimination of only a few infected cells at an early time
during infection, although histopathologically asympto-
matic, can result in a significant reduction in virus load,
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measurable at a later stage. Thus, the finding that low
numbers of antiviral effector cells suffice for protection can
be explained by early eradication of a few infected centers.
Two months after protection against a lethal infection by
adoptive transfer of CD8+ CD4- lymphocytes (Fig. 5),
persistent virus replication was detected in the salivary
glands of most and in the lungs of some survivors (Fig. 6),
although these individuals appeared healthy, had cured the
hemorrhages at the plantar site of infection, and had recon-
stituted their immune system, as manifested by a humoral
immune response to MCMV. There was no indication of a
role for antiviral antibody in the control of MCMV replica-
tion, as antibody titers in serum did not correlate with virus
titers in any of the organs tested. Persistent infection and
tissue distribution of MCMV during reconstitution of the
immune system after irradiation resemble the infection in
newborn mice, while in adult immunocompetent mice the
lungs are not affected and MCMV replication is confined to
the salivary glands, where it ceases after about 6 weeks (32;
G. M. Keil et al., unpublished observations).
The occurrence of substantial virus replication in the lungs
of phenotypically healthy survivors (Fig. 6) indicates that
infection at that site is not inevitably lethal. Adrenal cortical
dysfunction (31, 36) or failure in hematopoiesis (W. Mutter,
M. J. Reddehase, F. Busch, H.-J. Buhring, and U. H.
Koszinowski, manuscript in preparation) might turn out to
be a more decisive factor.
The most important aspect in our results concerns the
antigen specificity of protective effector cells. An in vivo
antiviral function could be attributed to CD8+ CD4- T
lymphocytes that displayed an in vitro CTL activity against
target cells selectively expressing nonstructural IE gene
products, but not against target cells presenting viral struc-
tural antigens (Fig. 4A). Recognition by CTL of nonstruc-
tural antigens encoded during the early and late phases of
MCMV replication could not be assessed, because selective
expression of early- and late-gene products in the absence of
IE gene products is technically not feasible as yet. Note that
pp89, the major IE protein (13), once synthesized during the
IE phase, remains detectable in infected cells throughout the
viral replication cycle and is synthesized again during the
late phase (27). For this reason, antigen-specific depletion of
lymphocytes and testing of the residual population was the
more conclusive approach to the identification of antiviral
effector cells. Significant reduction in both in vitro IE-
specific lytic activity and in vivo antiviral function by
preincubating sensitized CD8+ CD4- T lymphocytes on
monolayers that selectively expressed IE antigens positively
identified IE-specific T lymphocytes of the CD8 subset as in
vivo-operating antiviral effector cells.
It is still open to question why, in the immunocompetent
host, CTL specific for structural antigens of MCMV occur
less frequently than IE-specific CTL (30) and are often not
detectable at all. It has been discussed previously (30) that in
the immunocompetent host, infection is not productive in
tissues, except for the salivary glands, and hence effective
priming of CTL precursors specific for virion structural
antigens may not occur. Based on the present findings it
could be speculated that, by eradicating infected cells at an
early stage, the high in vivo antiviral efficacy of IE-specific
effector cells is directly responsible for the failure to gener-
ate a structural antigen-specific CTL response.
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